Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

This commentary describes the background to the recent FDA approval of rucaparib and olaparib for metastatic castration-resistant prostate cancer. It suggests, at this stage, that they should be primarily limited to those with BRCA1/2 mutations.


Journal of Clinical Oncology